13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001766721
Total reported value
$471.6M
$471.6M
14 檔
89.9%
During the Q3 2025 filing period, Aisling Capital Management LP (CIK: 0001766721) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $471.6M across 14 reported positions.
In Q3 2025, Aisling Capital Management LP displayed an active expansion posture, initiating 2 new positions and adding to 4 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 69.29% | -6.87% | +0.35% | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 14.39% | — | — | |
| 3 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 4.44% | -0.36% | — | |
| 4 | NUVB | Nuvation Bio Inc | Stock-Other | 2.40% | — | +16.52% | |
| 5 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 2.39% | +2.61% | — | |
| 6 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.97% | +1.20% | — | |
| 7 | CMPS | Compass Pathways PLC | Stock-Other | 1.50% | +2.64% | — | |
| 8 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.43% | -0.27% | — | |
| 9 | BMEA | Biomea Fusion Inc | Stock-Other | 0.91% | -0.02% | — | |
| 10 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.63% | +0.10% | — | |
| 11 | CALC | Calcimedica Inc | Stock-Other | 0.35% | — | — | |
| 12 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.18% | +0.15% | — | |
| 13 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.06% | +0.01% | — | |
| 14 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.05% | +0.01% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | VRNA | Verona Pharma PLC - Adr | +0.9% | — | Unchanged |
| 2 | NUVB | Nuvation Bio Inc | +0.9% | +16.52% | Add |
| 3 | BMEA | Biomea Fusion Inc | +0.3% | — | Add |
| 4 | CMPS | Compass Pathways PLC | +0.3% | — | Unchanged |
| 5 | SNDX | Syndax Pharmaceuticals Inc | +0.1% | — | Add |
| 6 | GLUE | Monte Rosa Therapeutics Inc | 0% | — | Unchanged |
| 7 | CALC | Calcimedica Inc | — | — | Unchanged |
| 8 | ACRS | Aclaris Therapeutics Inc | -0.1% | — | Unchanged |
| 9 | OKUR | Onkure Therapeutics Inc-a | -0.1% | — | Unchanged |
| 10 | MRKR | Marker Therapeutics Inc | -0.1% | — | Unchanged |
| 11 | BCAX | Bicara Therapeutics Inc | -0.6% | — | Unchanged |
| 12 | BBIO | Bridgebio Pharma Inc | -3.4% | +0.35% | Add |
| 13 | BBOT | Bridgebio Oncology Therapeut | — | NEW | New buy |
| 14 | SRRK | Scholar Rock Holding CORP | — | NEW | New buy |
| 15 | ✓ | Elevation Oncology Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Aisling Capital Management LP reported a total U.S. public equity portfolio value of $471.6M across 14 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BBIO, VRNA, SNDX) accounted for 89.9% of total reported equity market value during Q3 2025.
Top New Position Initiated
BBOT
市值: $6.5M
Top Position Liquidated / Trimmed
ELEVATION ONCOLOGY INC
前期市值: $734.5K
During Q3 2025, Aisling Capital Management LP's top holdings by market value included BBIO (69.3%)、VRNA (14.4%)、SNDX (4.4%). The largest single position, BBIO, represented 69.3% of total portfolio value.
In Q3 2025, Aisling Capital Management LP made 7 total portfolio adjustments, initiating 2 new buys, adding to 4 positions, trimming 0 holdings, and fully liquidating 1 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.